Aripiprazole + Risperidone/Quetiapine
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Psychotic Disorders
Conditions
Psychotic Disorders, Bipolar Disorder, Metabolic Syndrome X
Trial Timeline
Nov 1, 2012 → Feb 1, 2016
NCT ID
NCT01739127About Aripiprazole + Risperidone/Quetiapine
Aripiprazole + Risperidone/Quetiapine is a pre-clinical stage product being developed by Bristol Myers Squibb for Psychotic Disorders. The current trial status is completed. This product is registered under clinical trial identifier NCT01739127. Target conditions include Psychotic Disorders, Bipolar Disorder, Metabolic Syndrome X.
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01739127 | Pre-clinical | Completed |
Competing Products
14 competing products in Psychotic Disorders
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Olanzapine, Amantadine + Olanzapine and placebo | Eli Lilly | Phase 1 | 33 |
| risperidone IR and LAI formulation | Johnson & Johnson | Phase 1 | 33 |
| quetiapine | AstraZeneca | Phase 3 | 77 |
| Quetiapine | AstraZeneca | Phase 3 | 77 |
| Quetiapine | AstraZeneca | Phase 3 | 77 |
| quetiapine + olanzapine + risperidone | AstraZeneca | Pre-clinical | 23 |
| Asenapine 5-20 mg daily + Placebo 1-4 tablets daily | Merck | Approved | 85 |
| Ziprasidone HCL (oral) | Pfizer | Approved | 84 |
| Aripiprazole | Bristol Myers Squibb | Phase 3 | 76 |
| mifepristone + placebo | Corcept Therapeutics | Phase 3 | 72 |
| Miricorlilant + Miricorlilant + Placebo | Corcept Therapeutics | Phase 2 | 47 |
| Miricorilant + Fluvoxamine | Corcept Therapeutics | Phase 1 | 28 |
| Miricorilant + Placebo | Corcept Therapeutics | Phase 2 | 47 |
| Olanzapine + CORT118335 + Placebo | Corcept Therapeutics | Phase 1 | 28 |